http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
EFFECT OF ABOMASAL INFUSION OF ALANINE AND ASPARTIC ACID ON GROWTH HORMONE SECRETION IN SHEEP
Tanizawa, K.,Ashida, K.,Hosoi, E.,Matsui, T.,Yano, H. Asian Australasian Association of Animal Productio 1994 Animal Bioscience Vol.7 No.4
Effects of animo acids infusion into the abomasum on plasma growth hormone (GH) concentration were investigated using three wethers of 54 kg of average body weight. Wethers were infused with either 3.25 mmol/kg BW/day of sodium chloride solution (control), 3 mmol/kg BW/day of alanine (Ala), or 3 mmol/kg BW/day of aspartic acid (Asp) continuously for five days through an abomasum cathether in a $3{\times}3$ Latin square desing. On the day of starting infusion (day 0) and day 4 blood samples were collected from a jugular vein every fifteen minutes for six hours after feeding, and their GH concentrations were measured. Blood samples were also collected immediately before starting infusion (day 0), and before feeding of day 1, day 2 and day 4, and their plasma free amino acid concentrations were measured. In the animals infused with Ala, plasma free Ala concentration was increased by Ala infusion and it continued for four days. Plasma GH concentration of these animals increased on day 0, but this phenomenon disappeared on day 4. In the animals infused with Asp, the increase in plasma Asp concentration was observed only on day 1. Plasma GH concentration of these animals was not affected by Asp infusion. These results suggest that continuous Ala infusion stimulates GH secretion for a short period, but the effect would not last long, and that continuous Asp infusion does not affect plasma GH concentration.
Yamada, M.,Oeda, A.,Jung, J.,Iijima, M.,Yoshimoto, N.,Niimi, T.,Jeong, S.Y.,Choi, E.K.,Tanizawa, K.,Kuroda, S. Elsevier Science Publishers 2012 Journal of controlled release Vol.160 No.2
A bio-nanocapsule (BNC) is a hollow nanoparticle consisting of an approximately 100-nm-diameter liposome with about 110 molecules of hepatitis B virus (HBV) surface antigen L protein embedded as a transmembrane protein. BNC can encapsulate various drugs and genes and deliver them specifically to human hepatic cells based on the ability of HBV to recognize human hepatocyte, which is integrated in the N-terminal region of L protein. However, it is elusive whether the cellular attachment and entry into hepatic cells of BNC utilize the early infection mechanism of HBV. In this study, we have found that while all human hepatic cells show distinct affinities for BNC compared to non-hepatic cells, primary hepatocytes shows the highest efficiency for cellular binding and incorporation of BNC. Amounts of BNCs bound weakly and strongly to cell membranes and those entered into the cells varied significantly depending on the types of human hepatic cells. The weak and strong binding modes of BNC are likely mediated through binding to two distinct HBV receptors (heparin-mediated low-affinity and unidentified high-affinity receptors), which play major roles in the early infection mechanism of HBV. The rates of cellular uptake of BNC are similar to those reported for HBV. The BNCs incorporated into the cells are swiftly sorted to either early endosomes or macropinosomes and then to late endosomes and/or lysosomes. These findings strongly suggest that BNC is bound to and incorporated into human hepatic cells according to the early infection mechanism of HBV.